http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015141421-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e8432ebff5a06ee8a6ffec8cc7611fbd |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-94 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-94 |
| filingDate | 2014-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee6f868e8c2f8a0ffc09aead444df51b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a86caca6d28e3c9d5071460ae1a2661 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2572f863fab7542c78b11d0cf87fa0b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65cc2844ef0da3957ae1729311bea84d |
| publicationDate | 2015-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2015141421-A1 |
| titleOfInvention | 6,7-dialkoxy quinazoline derivatives and methods of treating drug resistant and other tumors |
| abstract | Compounds of formula (I) n n n n n n n n n n in which:n R 1 is: nn n n n n n n n n n andn R 2 is —CH 3 or —CH 2 CH 3 ; or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the compound of formula (I) and a pharmaceutically acceptable carrier. Processes for preparing the compound of formula (I). nn Methods of inhibiting a receptor tyrosine kinase in a subject in need thereof. Methods of inhibiting the growth of a tumor cell in a subject in need thereof. Methods of treating pancreatic cancer in a subject in need of treatment for pancreatic cancer. Methods of treating HER2 positive breast cancer in a subject in need of treatment for HER2 positive breast cancer. Methods of treating drug resistant non-small cell lung cancer in a subject in need of treatment for drug resistant non-small cell lung cancer. Each of these methods can include administering to the subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2008-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 305.